McKesson Corporation (NYSE:MCK) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On December18, 2017, McKesson Corporation (the “Company”) announced that it will appoint BrittVitalone as its Executive Vice President and Chief Financial Officer effective January1, 2018. Mr.Vitalone will replace James A. Beer who will be leaving the Company early next calendar year to become chief financial officer of Atlassian Corporation PLC.
Mr.Vitalone, age 48, is currently Senior Vice President and Chief Financial Officer of U.S. Pharmaceutical and McKesson Specialty Health, which includes responsibility for all day-to-day financial and accounting operations including long range planning and financial oversight of new strategic initiatives. From 2012 to 2014, Mr.Vitalone served as the Company’s Senior Vice President, Corporate Financial Planning and Analysis and Mergers& Acquisitions Finance with responsibility for the Company’s financial planning, cash flow forecasting, mergers an acquisitions and competitive analysis functions. From 2009 to 2012, he was Senior Vice President and Chief Financial Officer of the Company’s Medical-Surgical business, having joined the Company in 2006 as Vice President, Finance of the same business. Prior to joining the Company, Mr.Vitalone held a variety of financial leadership positions with General Electric Financial Assurance, CarMax, Inc. and Bausch& Lomb Inc.
Mr.Vitalone holds a Bachelor of Science degree in accounting from St. John Fisher College and is a certified public accountant. No family relationship exists between Mr.Vitalone and any of the Company’s directors or executive officers. Compensation for Mr.Vitalone associated with his new position has not been determined at the time of filing this report.
| Item 5.02 | Regulation FD Disclosure. |
On December18, 2017, the Company issued a press release announcing that Britt Vitalone will serve as the Company’s new Executive Vice President and Chief Financial Officer following Mr.Beer’s resignation effective December31, 2017. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained in this item, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 5.02 | Financial Statements and Exhibits. |
(d) Exhibits.
MCKESSON CORP ExhibitEX-99.1 2 d490920dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 McKESSON ANNOUNCES DEPARTURE OF JAMES BEER,…To view the full exhibit click here
About McKesson Corporation (NYSE:MCK)
McKesson Corporation (McKesson) is engaged in delivering pharmaceuticals, medical supplies and healthcare information technology. The Company operates through two segments: McKesson Distribution Solutions and Technology Solutions. The McKesson Distribution Solutions segment distributes drugs and equipment, and health and beauty care products across North America and internationally. The Distribution Solutions segment provides pharmaceutical solutions for biotech and pharmaceutical manufacturers, and practice management, technology, clinical support and business solutions to oncology and other specialty practices operating in the community setting. The Technology Solutions segment delivers clinical, patient care, financial, supply chain and strategic management software solutions, as well as connectivity, outsourcing and other services. Its McKesson Health Solutions portfolio includes ClarityQx, which is a payment technology.